TXNDC5抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-7: 293T, hela and hepg2 cell, human placenta and fetal muscle tissue, PC3 and HT-29 cell, Primary antibody: P08926(TXNDC5 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 7 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08926(TXNDC5 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08926(TXNDC5 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The TXNDC5 (Thioredoxin Domain-Containing 5) antibody is a research tool designed to detect and study the TXNDC5 protein, a member of the thioredoxin superfamily involved in redox regulation and protein folding. TXNDC5 is characterized by a conserved thioredoxin-like domain, enabling it to participate in disulfide bond formation and reduction, critical for cellular processes like endoplasmic reticulum (ER) stress response, apoptosis, and inflammation. It is expressed in various tissues, with elevated levels observed in cancer, cardiovascular diseases, and autoimmune disorders, where it may promote cell survival, angiogenesis, or pathological fibrosis.

This antibody is widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate TXNDC5's role in disease mechanisms. Studies highlight its involvement in ER stress pathways via interactions with chaperones like PDIA6. and its dysregulation in cancers (e.g., colorectal, liver) linked to tumor progression and chemoresistance. In cardiovascular research, TXNDC5 is implicated in endothelial dysfunction and atherosclerosis. Commercially available TXNDC5 antibodies are typically developed in rabbit or mouse hosts, validated for specificity and cross-reactivity across human and rodent homologs. Researchers utilize these antibodies to explore therapeutic targeting of TXNDC5 in conditions driven by oxidative stress or abnormal protein homeostasis.